Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3913]

Safety and efficacy of escalating doses of Hu5F9-G4 with rituximab in patients...

Dr Mark Roschewski - National Cancer Institute, Bethesda, USA

Safety and efficacy of escalating doses of Hu5F9-G4 with rituximab in patients with R/R DLBCL and indolent lymphoma ( Dr Mark Roschewski - National Cancer Institute, Bethesda, USA )

Combination of pegcrisantaspase and venetoclax in acute myeloid leukaemia

Dr Ashkan Emadi - University of Maryland Medical Centre, Maryland, USA

Combination of pegcrisantaspase and venetoclax in acute myeloid leukaemia ( Dr Ashkan Emadi - University of Maryland Medical Centre, Maryland, USA )

CD33 T cell recruiting antibody constructs for treatment of relapsed refractory...

Prof Marion Subklewe - LMU Hospital Munich, Munich, Germany

$CD33 T cell recruiting antibody constructs for treatment of relapsed refractory AML ( Prof Marion Subklewe - LMU Hospital Munich, Munich, Germany )$

Targeted treatment of AML using T cell recruiting antibody constructs

Prof Marion Subklewe - LMU Hospital Munich, Munich, Germany

Targeted treatment of AML using T cell recruiting antibody constructs ( Prof Marion Subklewe - LMU Hospital Munich, Munich, Germany )

PARP inhibitors olaparib and talazoparib as treatment for metastatic breast...

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

PARP inhibitors olaparib and talazoparib as treatment for metastatic breast cancer ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

Are PARP inhibitors a new standard of care option for MBC patients?

Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston...

Are PARP inhibitors a new standard of care option for MBC patients? ( Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston, USA )

The potential of PARP inhibitors in new cancer groups and in combination with...

Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston...

The potential of PARP inhibitors in new cancer groups and in combination with other treatments ( Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston, USA )

Anti-tumour activity of TAK-788 in NSCLC patients with EGFR exon 20 insertions

Dr Joel Neal - Stanford University, Stanford, USA

Anti-tumour activity of TAK-788 in NSCLC patients with EGFR exon 20 insertions ( Dr Joel Neal - Stanford University, Stanford, USA )

Comment: Enfortumab vedotin is an effective therapy and important development...

Dr Robert Dreicer, Dr Richard Schilsky and Prof Daniel Petrylak

Comment: Enfortumab vedotin is an effective therapy and important development for urotherial cancer patients ( Dr Robert Dreicer, Dr Richard Schilsky and Prof Daniel Petrylak )

Cancer care in Latin America

Dr Jean Rene Clemenceau - Hospital Angeles del Pedregal, Mexico City, Mexico

Cancer care in Latin America ( Dr Jean Rene Clemenceau - Hospital Angeles del Pedregal, Mexico City, Mexico )

Surveying cancer patients' mental health and financial problems

Dr Daniel Vorobiof - Sandton Oncology Centre, Sandton, South Africa

Surveying cancer patients' mental health and financial problems ( Dr Daniel Vorobiof - Sandton Oncology Centre, Sandton, South Africa )

Project Pink Blue: Fighting cancer through increasing awareness, screening...

Runcie C.W. Chidebe - Executive Director, Project PINK BLUE

Project Pink Blue: Fighting cancer through increasing awareness, screening, advocacy and patient navigation ( Runcie C.W. Chidebe - Executive Director, Project PINK BLUE )

More from ecancer